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agree that studies of smaller sample size should be 
interpreted cautiously. However, it is also important 
to recognize that statistical analyses are limited by the 
sample sizes. In instances where the rarity of a study 
topic limits total available sample size, we must con-
tinue to publish with the best statistical tools available 
and exercise caution in the interpretation.
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Reply: Nipple-Sparing Mastectomy in Patients 
with a History of Reduction Mammaplasty or 
Mastopexy: How Safe Is It? 
Sir:
Our study evaluated the safety of nipple-sparing 
mastectomy following prior breast reduction or mas-
topexy.1 It described our experience performing this 
higher risk procedure in a small subset of patients who 
were at a theoretically higher risk for complications.
We thank the letter authors for their comments 
and support their call for more rigorous studies in the 
plastic surgery literature. As outlined by Chung et al. in 
this Journal in 2009, our specialty would benefit from 
higher levels of evidence to definitively determine 
whether a technique is safe, an intervention effective, 
or a statistical finding accurate.2
The letter authors recommended a larger sam-
ple size with a multivariate regression model to con-
trol for factors such as skin flap necrosis, body mass 
index, smoking, cardiovascular disease, weight of the 
breast specimen, surgeon technique, and experience. 
The sample size necessary for a multivariate regres-
sion model using seven predictors with an anticipated 
size effect (f2) of 0.15, a statistical power level of 0.8, 
and a probability level of 0.05 would require over 100 
 nipple-sparing mastectomy breasts that underwent 
prior major breast surgery.
Combining the published experience from our 
institution with the patients reported at other major 
institutions would not reach the minimum number of 
breasts required for this multivariate regression analy-
sis.3,4 Furthermore, it would introduce other confound-
ing variables by comparing results across multiple 
institutions.
Our specialty should continue to strive for higher 
levels of evidence and statistically powered studies. We 
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Sir:
With great interest, we read the article entitled “Magnetic Resonance Imaging and Ultrasound 
Evaluation after Breast Autologous Fat Grafting Com-
bined with Platelet-Rich Plasma” by Fiaschetti et al.1 We 
would like to congratulate Dr. Fiaschetti et al. for their 
publication and their results.
Lipofilling is gaining popularity and is becoming 
a more common method for breast reconstruction 
after breast-conservation surgery, after mastectomy and 
radiotherapy treatment. Radiologists today are better 
able to differentiate neoplastic processes (recurrences 
or new cancers) from fat necrosis, as Fiaschetti et al. 
emphasized in their article. Nevertheless, we have some 
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concerns about the selection criteria for patients who 
may have breast reconstruction with lipofilling, espe-
cially if the fat graft is enriched with platelet-rich plasma. 
According to many reports, no increased occurrence of 
breast cancer or recurrence or metastatic spread was 
observed in patients who have had breast reconstruc-
tion with lipograft, except in cases of intraepithelial 
tumors, high-grade neoplasia with Ki-67 greater than or 
equal to 14, or in patients who had undergone quadran-
tectomy, as published by Petit et al.2
Experimental studies raise important questions 
about the potential detrimental effect of adipocytes on 
the stimulation of cancer growth and reappearance. 
Adipocytes and white adipose tissue-resident progeni-
tors are able to produce different growth factors, which 
could act on cancer cells through a paracrine activity. 
It is therefore mandatory to raise the question of recur-
rence risk for patients undergoing lipofilling in the 
area of the previous breast cancer treatment, particu-
larly after conservative treatment.3
In this study, Fiaschetti et al. evaluated the radio-
logic aspects of 24 breasts of 15 women who underwent 
lipofilling to correct the results of surgery or solely for 
aesthetic reasons. All patients underwent breast lipo-
filling with adipose tissue enriched with platelet-rich 
plasma. Anamnesis, clinical examination, ultrasound, 
mammography, and magnetic resonance imaging were 
performed before lipoinjection. Ten of the 15 patients 
have had breast reconstruction using lipofilling with 
platelet-rich plasma within 3 months after removal of 
the tumor and 6 months after the end of radiotherapy/
chemotherapy (seven patients after breast-conserving 
surgery and three patients after a radical mastectomy).
In 10 breast cancer patients of this study, it is not 
indicated whether the histologic type of cancer or its 
characteristics (e.g., Ki-67 index) have been considered 
as important for including or excluding patients from 
the adipose enriched with platelet-rich plasma proce-
dure. For lack of scientific evidence that proves the safety 
of lipofilling of the breast in patients with a history of 
cancer, the American Society of Plastic Surgeons and the 
French Society of Plastic, Reconstructive and Aesthetic 
Surgery recommend caution in the use of lipofilling, par-
ticularly if enriched.4 As suggested by the major world 
societies of plastic surgery, we think that the use of adi-
pose tissue enriched with platelet-rich plasma, to increase 
fat-graft survival, must require strict selection criteria for 
patients.5 In this study, though well conducted, there is 
no mention of selection criteria. This could be a wrong 
message, especially for young surgeons.
We think that in breast-conservation surgery, the 
lipofilling should be performed at least 3 (or 5) years 
(not months) after the removal of the breast tumor, 
and the enhanced fat-grafting should be discouraged 
until clinical studies provide evidence regarding safety.5
Fat grafting after mastectomy is a good surgi-
cal option with limited risk. It can be combined with 
other reconstruction techniques, including prostheses 
implants; however, in patients who have undergone a 
mastectomy, there is an increased risk for developing 
breast cancer also on the contralateral side. For this 
reason, we suggest that lipografting on the contralat-
eral breast should be avoided.
In aesthetic surgery, breast augmentation with 
lipografting is a surgical option in women without 
a personal or family history of cancer. Some authors 
even suggest performing genetic testing for BRCA1 
and BRCA2 mutations; radiologic controls at least 1, 5, 
and 10 years after grafting; and then entering normal 
breast cancer screening programs afterward.
These recommendations are based on the onco-
logically unclear situation of fat grafting after tumor 
surgery and arise from the need to reduce hazard-
ous treatment by careful patient selection. Today, no 
informed consent can be given to our patients stating 
that lipofilling (with or without platelet-rich plasma) 
does not stimulate fueling of dormant cancer cells or 
eventually induce new cancer cells. We should always 
keep in mind that today’s patients know their disease 
and treatment options. They also have a greater num-
ber of tools with which to understand breast recon-
struction techniques (through specific Web sites and 
outreach programs on the disease such as Breast 
Reconstruction Awareness Day). Even for medicolegal 
reasons, surgeons should act prudently in selecting the 
patients and informing them (with a specific informed 
consent) that there is limited scientific evidence avail-
able to verify the safety of fat transfer procedures in 
patients with a history of breast cancer surgery.
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Re: Reply: The Poly Implant Prothèse Debacle
Sir:
We welcome Maijers and Neissen drawing atten-tion to the nonsurgical issues surrounding Poly 
Implant Prothèse implants.1 Although initially unset-
tled in the United Kingdom, fortunately, last week’s 
report from the Medicines and Healthcare Products 
Regulatory Agency2 has again failed to evidence any 
harmful issues with constituent products. Although it is 
surprising that any breast-augmented women continue 
to decline follow-up given the global health scare, it is 
reassuring to have comparable figures using different 
tools of measurement from both  Britain and Holland.
Although not wishing to prolong debate unnecessar-
ily, there is a major error in the above-mentioned reply,1 
which mandates correction because of a complete inver-
sion of our data.3 Perhaps linguistic misapprehension 
is at fault, but Figure 2 clearly displays device durabil-
ity according to year of implantation and not duration 
of implantation (that is Figure 3). To clarify, we docu-
mented median time to rupture for implants implanted 
in the year 2000 to be 10.5 years. The same measure from 
2005 was 5.8 years, with the intervening years declining in 
a broadly linear fashion. It is obvious that implant integ-
rity decreases with time; however, we have documented 
something entirely different with Poly Implant Prothèse 
devices, and this runs counter to any previously pub-
lished data. As a smaller point, with our original article 
being received for publication on December 30, 2011, 
and that by Maijers and Neissen being received on Janu-
ary 8, 2012, the claim of primacy is factually incorrect.
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Facial Changes Caused by Smoking: 
A Comparison between Smoking and 
Nonsmoking Identical Twins 
Sir:
I wish to acknowledge the article entitled, “Facial Changes Caused by Smoking: A Comparison between 
Smoking and Nonsmoking Identical Twins,” by Okada 
et al.1 The authors’ creative use of photographic facial 
contrasts between smoking and nonsmoking twins 
identified specific features of facial aging consequent 
to tobacco use.
However, a serious methodologic flaw is the inves-
tigators’ failure to document the procedures by which 
the zygosity of the twin pairs was determined; the 
only mention of the twins’ zygosity (identical) occurs 
in the title. Accurate assessment of twins as monozy-
gotic (identical) or dizygotic (fraternal) is crucial to 
the design of any twin study and to the interpretation 
of the data. The identification of smoking-discordant 
monozygotic twins constitutes a naturally occurring co-
twin control study, which I believe the investigators had 
in mind.2 Specifically, the nonsmoking twin provides 
the perfect genetic control against which to assess the 
effects of smoking on the part of the co-twin. In the 
event that dizygotic twins were included in the sample, 
the basic logic of the co-twin control study would have 
been violated. More importantly, the conclusions from 
the study would have been misleading. That is because 
the differential aging of smoking-discordant dizy-
gotic  co-twins could be associated with both genetic 
and experiential factors, thereby confounding these 
sources of explanation.
Accurate diagnosis of zygosity requires DNA test-
ing for approximately 15 short tandem repeat markers 
that can be easily obtained from buccal smears (cheek 
swabs).3 Standard physical resemblance questionnaires 
developed to show excellent agreement with results 
from DNA testing or blood group analysis can be sub-
stituted when necessary. Possibly, a description of the 
zygosity testing for the twins in this study will be forth-
coming. This information will greatly increase readers’ 
confidence in such important findings.
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